The field of treatment of aortic stenosis (AS) has undergone tremendous changes in the past few years. Recent clinical trials showed positive results for patients with low risk with severe AS, which expands the number of untreated patients who could benefit from intervention. This webcast will discuss identification of patients, the importance of the multidisciplinary heart team, the role of the internist and clinical cardiologist in evaluation, asymptomatic patients, complications, procedural flow, and patient follow-up.
CME ACCREDITATION AND DESIGNATION
The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cardiovascular Research Foundation designates this activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians should claim only the credit commensurate with the extent of their participation in the activity. Documentation of awarded credit is provided for participants in exchange for completed activity evaluations. Evaluation by questionnaire will address content, presentation effectiveness, possible bias, and future educational needs.
To obtain CME credit for this activity, participants must review all CME information, view all presentations in their entirety, and complete the Activity Evaluation Form. If you have any questions, please contact Joe Heard at jheard@crf.org .
By the end of this program, participants should be able to:
• Identify low risk AS patients who would benefit from TAVR
• Describe the anatomic characteristics that guide the treatment pathway for AS patients
• Define the clinical pathway for concomitant CAD and AS
This educational activity is designed for interventional cardiologists, clinical cardiologists, and other healthcare professionals involved in the management of patients with valvular heart disease.
It is the policy of the Cardiovascular Research Foundation to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and therefore, does not compromise the scientific integrity of the educational activity.
Discussion of off-label product usage is made at the sole discretion of the faculty. Off-label product discussion and usage is not endorsed by the Cardiovascular Research Foundation or the course directors of this activity.
All Planners (Directors, Co-Directors and Chairs) and Faculty participating in continuing medical education activities sponsored by the Cardiovascular Research Foundation are required to disclose to the activity audience any real or apparent conflicts of interest related to the content of their presentations. Anyone in noncompliance with this policy is not permitted to participate in this activity.
KEY: (G/R) Grant Support/Research Contract (C/H/S) Consultant Fee/Honoraria/Speaker’s Bureau (E/S/O) Equity/Stock(s)/Options (R/I) Royalty/Intellectual Property Rights (S) Salary/Salary Support (O) Other Financial Benefit
Moderator:
Vinod Thourani – (G/R) (C/H/S) Edwards Lifesciences
Panel:
Adam Greenbaum – (E/S/O) Transmural Systems; (O) Proctor honoraria: Edwards Lifesciences; Proctor honoraria: Medtronic
Samir Kapadia – Nothing to disclose
Content Reviewer(s):
Gary S. Mintz, MD – Nothing to disclose
Joe Heard, MHA - Nothing to disclose
Colleen Whelan - Nothing to disclose
This program is sponsored by the Cardiovascular Research Foundation and supported through an unrestricted grant from Edwards Lifesciences. The Cardiovascular Research Foundation ensures that its programs are educational and meet the needs of the target audience. This program was developed without influence from commercial supporters.